Lancet Oncology Commission on radiotherapy and theranostics – The Lancet Oncology
John Christodouleas, GU Radiation Oncologist at PENN, shared a post by The Lancet Oncology on X, adding:
“We argued:
1. Public and private payers aiming to improve radiotherapy access while controlling costs should incentivize SBRT, yet most create disincentives.
2. No one owns a patent on radiotherapy. The lack of resources directed toward studying its optimal delivery through clinical research is a market failure. Governments must step in to address the disparity between radiotherapy’s critical role in cancer care and the lack of research funding.
3. The latest Lancet Oncology Commission is another tremendous resource for anyone interested in radiotherapy at a systems level.”
Quoting The Lancet Oncology:
“Linked to Lancet Oncology Commission on radiotherapy and theranostics: Comment: Focus where it matters: turning insights into advocacy — John Christodouleas, Therese Linde, & Gustaf Salford, Elekta.”
Focus where it matters: turning insights into advocacy
Authors: John Christodouleas, Therese Linde and Gustaf Salford.
Source: John Christodouleas/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023